-+ 0.00%
-+ 0.00%
-+ 0.00%

Kangyuan Pharmaceutical (600557.SH) received a notice of approval for clinical trials of Shiwei Enteric Granules

Zhitongcaijing·10/22/2026 10:41:13
Listen to the news

Zhitong Finance App News, Kangyuan Pharmaceutical (600557.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for Shiwei Gansu Granules issued by the State Drug Administration. Shiwei Intestinal Granules are clinical empirical formulations formed under the theoretical guidance of traditional Chinese medicine. They have the effects of strengthening the spleen, clearing the intestines, and relieving diarrhea, and are clinically used for ulcerative colitis caused by spleen deficiency.